01 / CONTROLLED RELEASE MATRIX
Delayed Intestinal Absorption
Polymer-coated matrix delays paroxetine release until passing through the stomach, significantly mitigating nausea and gastric irritation while ensuring 24h plasma stability.
Blessme · Antidepressants & Anxiolytics
Paroxetine CR + Clonazepam Tablets - PAXOTIN-CR-PLUS
PAXOTIN-CR-PLUS is an advanced controlled-release neuropsychiatric formulation combining Paroxetine Hydrochloride IP equivalent to Paroxetine 12.5 mg (CR) with Clonazepam IP 0.5 mg by Blessme, Dellwich Lifescience LLP. Specifically indicated for major depressive disorder comorbid with panic attacks, generalized anxiety, and social phobia, delivering immediate GABAergic tranquilization while establishing sustained 24-hour serotonergic restoration with superior gastric tolerability.
Controlled-Release Matrix
Narcotic / Schedule H
Pan-India Supply
Product SpecificationsAbout Paroxetine CR + Clonazepam
About Paroxetine CR + Clonazepam
(PAXOTIN-CR-PLUS)
Detailed pharmaceutical specifications, active API monograph compliance, controlled-release matrix synergy, and 10x10 aluminium strip packaging details for PAXOTIN-CR-PLUS.
Blessme · Antidepressant & Anxiolytic
Paroxetine CR + Clonazepam - PAXOTIN-CR-PLUS
PAXOTIN-CR-PLUS provides 12.5 mg Paroxetine CR paired with 0.5 mg Clonazepam. Formulated for patients suffering from depression complicated by recurrent panic attacks, intense somatic anxiety, and panic with agoraphobia with reduced nausea.
12.5 mg Controlled-Release Paroxetine Ensures 24h SERT Inhibition0.5 mg Clonazepam Halts Immediate Panic Surges & Somatic DreadEnteric Polymeric Matrix Minimizes Gastric Upset & Nausea 10x10 Aluminium Foil Strip Format for Maximum Protection Strict Indian Pharmacopoeia Quality Standards
- Product Brand Name
- PAXOTIN-CR-PLUS
- Active Pharmaceutical Ingredients
- Paroxetine HCl IP eq. to Paroxetine 12.5 mg (CR) + Clonazepam IP 0.5 mgVerified IP
- Therapeutic Class
- Controlled-Release SSRI Antidepressant & Benzodiazepine Anxiolytic
- Dosage Form
- Controlled-Release Film-Coated Tablet
- Strength Formulation
- 12.5 mg Paroxetine CR + 0.5 mg Clonazepam
- Packaging Standard
- 10x10 Aluminium Foil Strips (100 Tablets per Box)
- Regulatory Category
- Narcotic Drug
- Marketing Division
- Blessme · Neuro & Psychiatric Products
- Manufacturing Standard
- WHO-GMP & ISO 9001:2015 Certified Clean-Room Compression
- Storage Condition
- Store below 25°C in a dry place. Protect from light and moisture.
- Country of Origin
- India
Clinical & Commercial MonographParoxetine CR + Clonazepam Tablet & PAXOTIN-CR-PLUS
Paroxetine CR + Clonazepam Tablet & PAXOTIN-CR-PLUS
Complete Medical & Supply Guide
In-depth pharmacological evaluation of Paroxetine CR 12.5 mg + Clonazepam 0.5 mg tablets, marketed as PAXOTIN-CR-PLUS by Blessme (Dellwich Lifescience LLP). Covers acute panic termination, depression treatment, and pharmaceutical supply across India.
What is PAXOTIN-CR-PLUS (Paroxetine CR 12.5 mg + Clonazepam 0.5 mg)?
PAXOTIN-CR-PLUS is a specialized oral neuropsychiatric formulation combining a controlled-release formulation of the selective serotonin reuptake inhibitor (Paroxetine CR 12.5 mg) with a high-affinity positive GABA_A modulator (Clonazepam 0.5 mg).
When psychiatrists initiate antidepressant therapy in patients with panic disorder or anxious depression, standard SSRIs can paradoxically aggravate jitteriness during the first 10 to 14 days. PAXOTIN-CR-PLUS bridges this critical vulnerability by delivering immediate high-potency anxiolytic coverage via Clonazepam while Paroxetine CR steadily upregulates neuroplastic mood resilience.
Clinical Uses & Evidence-Based Indications
Approved neurological and psychiatric indications for PAXOTIN-CR-PLUS include:
- Major Depressive Disorder (MDD) with Anxious Distress: Restores positive affect while relieving somatic dread.
- Panic Disorder with or without Agoraphobia: Aborts recurrent panic attacks and reduces anticipatory fear.
- Generalized Anxiety Disorder (GAD): Provides rapid and sustained stabilization of chronic worry.
- Social Anxiety Disorder (Social Phobia): Facilitates social exposure and reduces performance terror.
- Obsessive-Compulsive Spectrum Symptoms: Paroxetine provides foundational serotonergic antiobsessional efficacy.
Neurochemical Mechanism of Action: Serotonergic & GABAergic Synergy
Paroxetine is recognized as one of the most potent inhibitors of the serotonin transporter (SERT), preventing 5-HT reuptake and steadily increasing serotonergic neurotransmission in cortical and limbic synapses over a 2 to 4-week neuroplastic adaptation period.
Simultaneously, Clonazepam 0.5 mg acts as a high-potency positive allosteric modulator on the GABAA receptor-chloride ion channel complex. By increasing chloride influx, it hyperpolarizes limbic neurons, immediately terminating acute panic attacks, motor restlessness, and severe autonomic surges from the very first dose.
Why the Controlled-Release Matrix Matters
Advantages of Paroxetine CR over Immediate-Release:
- Reduced Gastric Nausea: Enteric polymers delay dissolution until the small intestine, eliminating stomach irritation.
- Smooth 24-Hour Plasma Profile: Prevents peak-to-trough fluctuations, reducing peak-associated dizziness and fatigue.
- Superior Compliance: Patients rarely discontinue therapy prematurely due to gastrointestinal intolerance.
Dosage Guidelines & Administration Method
PAXOTIN-CR-PLUS must be taken strictly in accordance with medical advice:
- Administration Time: Typically 1 tablet once daily, preferably in the morning or at bedtime with water.
- Swallow Whole: Take with water; do not crush, split, or chew the tablet.
- With or Without Food: Can be taken with meals to minimize any potential mild nausea.
- Gradual Tapering: Discontinue gradually under psychiatric guidance to avoid rebound anxiety and discontinuation symptoms.
Critical Safety Warning - Schedule H / Narcotic Controlled Substance
PAXOTIN-CR-PLUS contains Clonazepam, which carries potential for dependence and habit formation with prolonged therapy. Do not consume alcohol during therapy. Contraindicated with monoamine oxidase inhibitors (MAOIs). Dispensed strictly against a valid medical prescription.
Quality & Production
Pharmaceutical Quality Assurance & Compliance
PAXOTIN-CR-PLUS is manufactured in WHO-GMP certified facilities adhering to Schedule M protocols, ensuring micro-blend homogeneity and maximum packaging stability.
02 / PROTECTIVE PACKAGING
High-Barrier Aluminium Strip
Tamper-evident 10x10 aluminium-aluminium foil packaging shields active APIs against atmospheric moisture and thermal degradation for extended shelf stability.
03 / PHARMACOPOEIA DOSSIERS
COA & Dissolution Profiles
Every batch is verified through authenticated Certificates of Analysis (COA), multi-point dissolution profiling, and HPLC active assay validation complying with IP standards.
04 / WHO-GMP COMPLIANCE
Schedule M Manufacturing
Produced in state-of-the-art cleanroom manufacturing units in Gujarat adhering to automated compression, online check-weighing, and Good Laboratory Practices (GLP).
Clinical Profile & Precautions
Approved Indications & Regulatory Guidelines
Prescribing guidance, contraindications, and drug interactions for Paroxetine CR 12.5 mg + Clonazepam 0.5 mg tablets.
Prescription-Only Schedule H / Narcotic Medication Notice
PAXOTIN-CR-PLUS is a Schedule H prescription drug. Not for OTC sale. Do not consume alcohol during therapy. Exercise caution when driving or operating machinery.
Clinical Indications Profile
Approved neurological and psychiatric indications for PAXOTIN-CR-PLUS:
- Major Depressive Disorder: Rebalances core serotonergic neurotransmission with low nausea.
- Acute Panic Disorder: Rapidly aborts panic attacks and anticipatory fear.
- Refractory GAD: Controls severe generalized anxiety and sleep disruption.
- Agoraphobia with Panic: Suppresses panic triggers in challenging environments.
Contraindications & Precautions
Key contraindications and monitoring requirements:
- MAOI Interaction: Never use concurrently with MAOIs; observe a 14-day washout period.
- Swallow Whole: Do not split or chew the tablet to preserve the CR matrix.
- Alcohol Prohibition: Dangerous synergism leading to severe hypotension and CNS depression.
- Gradual Discontinuation: Taper slowly under physician direction.
Manufacturing & Marketing
Dellwich Lifescience LLPBlessme · Neuro & Psychiatric Division
About Dellwich Lifescience
Trusted Neuro & Psychiatric Pharmaceutical Manufacturer in Ahmedabad, Gujarat
Dellwich Lifescience LLP is an established pharmaceutical company based in Science City, Ahmedabad, Gujarat, dedicated to advanced formulation technology, uncompromising quality assurance, and ethical healthcare supply. Through our specialized neurology division, Blessme, we manufacture and market superior neuro-psychiatric treatments, including PAXOTIN-CR-PLUS (Paroxetine CR 12.5 mg + Clonazepam 0.5 mg Tablets).
We support PCD pharma franchise partners, hospital supply chains, and contract manufacturing clients across India with guaranteed supply security, validated product dossiers, and prompt dispatch.
Commercial PartnershipsPAXOTIN-CR-PLUS Supply &
PAXOTIN-CR-PLUS Supply &
Pharmaceutical Distribution
Whether you are seeking PAXOTIN-CR-PLUS for district monopoly PCD franchise distribution, third-party contract manufacturing, or hospital bulk procurement, Dellwich Lifescience LLP delivers dependable supply and competitive trade margins.
Exclusive Monopoly PCD Franchise
Secure district-level monopoly marketing rights for PAXOTIN-CR-PLUS and the complete Blessme neuropsychiatry range with visual aids, product glossaries, and promotional input support.
Third-Party Contract Manufacturing
Turnkey manufacturing solutions for pharmaceutical marketing companies with flexible batch runs, rapid production turnaround, and full regulatory dossier support from Ahmedabad.
Hospital & Institutional Procurement
Direct bulk pharmaceutical supply agreements for multispecialty hospital chains, psychiatric nursing homes, and institutional medical tenders with prompt pan-India logistics.
Blessme · PAXOTIN-CR-PLUS
Why Choose PAXOTIN-CR-PLUS Tablets?
When sourcing Paroxetine CR Clonazepam tablets in India, PAXOTIN-CR-PLUS by Blessme provides exceptional clinical efficacy, reliable blister packaging, and comprehensive B2B franchise support.
WHO-GMP Certified Purity
Manufactured in accredited facilities using IP grade APIs, ensuring exact active content uniformity and controlled dissolution.
High-Barrier Aluminium Packaging
Tamper-evident, moisture-resistant aluminium strips protect tablets from ambient humidity and transport friction.
Pan-India Dispatch from Ahmedabad
Direct factory dispatch with GST invoicing, verified batch COA, and dependable logistics coverage across all Indian states.
Monopoly PCD Franchise Rights
Exclusive district-level franchise rights for PAXOTIN-CR-PLUS and the Blessme portfolio with promotional visual aids.
Comprehensive Regulatory Dossiers
Certificates of Analysis (COA), stability testing data, and MSDS readily available for institutional audits and tenders.
Direct Manufacturer Support
Direct access to Dellwich Lifescience product specialists for quick quotes, customized bulk orders, and customer assistance.
Common Questions
Frequently Asked Questions about PAXOTIN-CR-PLUS
Authoritative answers to clinical, commercial, dosage, and regulatory questions regarding Paroxetine CR + Clonazepam tablets.
What is PAXOTIN-CR-PLUS and what does it contain?
PAXOTIN-CR-PLUS is a controlled-release oral prescription tablet from the Blessme division of Dellwich Lifescience. It contains Paroxetine Hydrochloride IP equivalent to Paroxetine 12.5 mg (in controlled-release form) and Clonazepam IP 0.5 mg, formulated for major depression comorbid with acute panic attacks and severe anxiety.
Why is Paroxetine CR preferred over conventional immediate-release Paroxetine?
Conventional immediate-release paroxetine dissolves rapidly in the stomach, which can cause significant nausea, dyspepsia, and gastric distress. Paroxetine CR uses a specialized enteric matrix that delays release until the tablet reaches the small intestine, providing a smooth 24-hour plasma curve with dramatically lower rates of nausea.
How does the combination in PAXOTIN-CR-PLUS work?
Paroxetine CR is one of the most potent selective serotonin reuptake inhibitors (SSRIs), elevating synaptic serotonin (5-HT) to resolve core depressive symptoms and obsessive worry over 2 to 4 weeks. Simultaneously, Clonazepam 0.5 mg acts immediately on GABA_A receptors to stimulate inhibitory chloride influx, terminating acute panic dread and somatic restlessness from day one.
When should PAXOTIN-CR-PLUS be taken?
Psychiatrists typically advise taking PAXOTIN-CR-PLUS once daily in the morning or at bedtime. It should be taken with or after meals. If daytime drowsiness is observed due to the 0.5 mg Clonazepam component, bedtime administration is frequently recommended.
Can the tablet be crushed or divided?
No. PAXOTIN-CR-PLUS must be swallowed whole. Dividing, chewing, or crushing the tablet ruptures the controlled-release membrane, causing rapid drug release that can lead to acute side effects and loss of 24-hour therapeutic coverage.
Does PAXOTIN-CR-PLUS cause daytime drowsiness?
Yes. Due to the Clonazepam 0.5 mg component, mild-to-moderate sedation, drowsiness, or lightheadedness can occur, particularly during initial days of therapy. Patients should avoid driving or operating heavy machinery until individual tolerance is established.
Can PAXOTIN-CR-PLUS be stopped suddenly?
No. Abrupt stoppage can precipitate severe withdrawal symptoms (sensory disturbances, dizziness, electric shock sensations, rebound panic, and insomnia) due to simultaneous cessation of the SSRI and benzodiazepine. Gradual dose tapering under psychiatric direction is mandatory.
Can I drink alcohol while taking PAXOTIN-CR-PLUS?
Alcohol is strictly prohibited. Combining alcohol with Paroxetine and Clonazepam can cause dangerous central nervous system depression, extreme sedation, respiratory suppression, and memory blackouts.
Is PAXOTIN-CR-PLUS habit-forming?
The Clonazepam component belongs to the benzodiazepine class and carries potential for dependence and tolerance when taken continuously over long periods. Clinicians typically re-evaluate the patient after 4 to 8 weeks to determine tapering strategies.
Can pregnant women take PAXOTIN-CR-PLUS?
Use during pregnancy is contraindicated unless specifically evaluated and determined to be essential by a medical specialist, as both Paroxetine and Clonazepam can pose risks to the developing fetus.
How is PAXOTIN-CR-PLUS packaged?
PAXOTIN-CR-PLUS is supplied in premium 10x10 aluminium-aluminium foil strips (100 tablets per box) manufactured with high-barrier foil to guarantee extended shelf life across all Indian climate conditions.
How can distributors apply for PCD franchise monopoly for PAXOTIN-CR-PLUS?
Pharmaceutical distributors and stockists can submit an enquiry through our online form below or contact our neuropsychiatry franchise desk at +91 99099 31992 for monopoly territory allocation.
Does Dellwich Lifescience offer third-party manufacturing for Paroxetine CR combinations?
Yes. Dellwich Lifescience provides turnkey contract manufacturing for Paroxetine CR + Clonazepam tablets with WHO-GMP certification, customized branding, and on-time shipment dispatch from Ahmedabad.
Where is Dellwich Lifescience headquartered?
Dellwich Lifescience LLP is headquartered on Science City Road, Ahmedabad, Gujarat, India, with rapid logistics connections across all Indian states.
Direct Pharmaceutical Enquiry
Need Verified Information or Bulk Supply of PAXOTIN-CR-PLUS?
Connect directly with Dellwich Lifescience LLP for trade pricing, district monopoly PCD rights, third-party manufacturing, or institutional hospital tender supplies.
Direct Manufacturer Pricing & Transparent MOQ
Exclusive PCD Monopoly Rights for Designated Districts
Fast Dispatch from Ahmedabad with GST Invoicing
Comprehensive Marketing, Visual Aids & Promotional Inputs
Quick Assistance & Orders
Enquire About PAXOTIN-CR-PLUS
Get wholesale pricing, PCD franchise monopoly rights, and technical documentation for Paroxetine CR 12.5 mg + Clonazepam 0.5 mg Tablets.